Atypical Progressive Supranuclear Palsy (PSP)

Atypical progressive supranuclear palsy (PSP) is a brain disease where certain cells slowly get damaged by an abnormal protein called 4-repeat tau. This damage makes eye movements slow or difficult (especially looking up or down), causes early falls, stiffness, slow movement, speech and swallowing trouble, and changes in thinking or mood. Different people can look different (there are “variants”), so doctors use specific clinical signs to make the diagnosis. At this time there is no proven cure. Treatment focuses on safety, comfort, independence, and managing symptoms with therapy, lifestyle changes, and medicines. PubMed+3PMC+3PubMed+3

Progressive Supranuclear Palsy (PSP) is a degenerative brain disease. It mainly affects the brainstem and deep brain structures that control eye movements, balance, walking, speech, and thinking. The word “supranuclear” means the problem sits above the eye-movement nerves, in control centers that command those nerves. The disease usually gets worse over years. It belongs to the “tauopathies,” because an abnormal protein called 4-repeat (4R) tau builds up in brain cells and glia. These tau clumps damage and kill cells. That causes slow vertical eye movements, early falls, stiff body posture, soft or slurred speech, trouble swallowing, and thinking or behavior changes. Not every person has the same first symptoms. Many people do not fit the “classic” picture early on. Those people are said to have an “atypical PSP variant,” such as PSP-parkinsonism, PSP with speech/language problems, PSP with gait freezing, or PSP with corticobasal features. Modern diagnostic criteria from the Movement Disorder Society describe these variants clearly to help earlier, more accurate diagnosis. NCBI+2Movement Disorders+2

Other names

Doctors may use several labels that all sit under the PSP umbrella:

• PSP (Steele–Richardson–Olszewski disease). The historic name for the core disorder. NCBI

• PSP–Richardson’s syndrome (PSP-RS). The “classic” form with early falls and vertical gaze problems. Perelman School of Medicine

• PSP–parkinsonism (PSP-P). Looks like Parkinson’s disease at first (bradykinesia, limb rigidity), with less early eye signs. Perelman School of Medicine

• PSP with predominant ocular motor dysfunction (PSP-OM). Eye movement slowing is the leading sign early on. Perelman School of Medicine

• PSP with postural instability (PSP-PI). Early falls from poor balance without clear early gaze palsy. Perelman School of Medicine

• PSP with speech/language disorder (PSP-SL). Early nonfluent speech or apraxia of speech dominates. PMC

• PSP with corticobasal syndrome (PSP-CBS). Limb apraxia, dystonia, or “alien limb” features resembling corticobasal degeneration. PMC

• PSP with frontal presentation (PSP-F). Apathy, impulsivity, planning problems, or social changes predominate. Perelman School of Medicine

• PSP with pure akinesia and gait freezing (PSP-PAGF). Marked gait freezing and small steps without tremor or limb rigidity early. Perelman School of Medicine

Types

Below are the main variants emphasized in modern criteria and reviews:

1. PSP-P (parkinsonism-predominant). Parkinson-like signs with limited early eye findings; often modest levodopa response early. Perelman School of Medicine

2. PSP-SL (speech/language). Effortful, halting speech (apraxia of speech) or nonfluent/agrammatic aphasia precedes other signs. PMC

3. PSP-CBS (corticobasal). Asymmetric limb rigidity, apraxia, myoclonus, dystonia, cortical sensory loss. PMC

4. PSP-F (frontal). Executive dysfunction, disinhibition, apathy, or socially inappropriate behavior lead the picture. Perelman School of Medicine

5. PSP-PAGF (pure akinesia with gait freezing). Freezing of gait and start hesitation for years before other core signs appear. Perelman School of Medicine+1

6. PSP-OM (ocular motor). Early vertical saccade slowing and later gaze palsy dominate; helpful for early recognition. PMC

7. PSP-PI (postural instability). Early falls and axial stiffness without clear early gaze palsy. Perelman School of Medicine

Note: All of these share the same underlying 4R tau pathology and many will evolve toward the “classic” PSP-RS pattern over time. The MDS-PSP criteria were built to capture this spectrum. Perelman School of Medicine

Causes

PSP is usually not caused by one outside trigger. It is mostly sporadic. “Causes” here means biological drivers and known risk factors that contribute to disease start and spread.

1. Abnormal 4R tau protein accumulation. The core disease process; tau misfolds and clumps in neurons and glia, harming circuits controlling eyes, posture, and speech. NCBI

2. Microtubule dysfunction. Tau normally stabilizes microtubules; faulty tau disrupts transport inside cells, leading to cell stress and death. PMC

3. MAPT (tau) H1 haplotype risk. A common genetic background on chromosome 17 raises PSP risk in many people. PMC+2Frontiers+2

4. Other genetic risk loci (e.g., MOBP, STX6, EIF2AK3). Genome-wide studies implicate additional genes that affect cell trafficking and stress responses. PMC

5. Ageing. Risk rises with age; disease usually begins in the 60s–70s. Ageing processes increase tau vulnerability. NCBI

6. Neuroinflammation. Activated microglia and astrocytes around tau deposits may fuel progression. PMC

7. Mitochondrial stress and oxidative injury. Energy failure in affected neurons promotes degeneration. (Mechanistic review context.) PMC

8. Axonal transport failure. Disrupted microtubules and tau lead to stalled cargo movement and synaptic dysfunction. PMC

9. Prion-like tau spreading. Misfolded tau may propagate along brain networks, explaining step-wise spread of symptoms. PMC

10. White-matter tract injury. Degeneration of cerebellar and brainstem pathways worsens balance and eye control. PMC

11. Dopaminergic terminal loss. Loss in striatum causes bradykinesia and rigidity; it is seen on DAT imaging but is not specific. Biospective Imaging

12. Brainstem (midbrain) atrophy. The midbrain shrinks early; this is a structural hallmark on MRI. PMC+1

13. Saccadic network dysfunction. Burst neurons and their circuits slow vertical saccades even before full gaze palsy. PMC

14. Frontostriatal circuit degeneration. Frontal and basal ganglia injury drives apathy, impulsivity, and executive problems. PMC

15. Speech and language network degeneration. Cortical–subcortical loops that plan and execute speech are affected in PSP-SL. PMC

16. Gait-freezing network failure. Brainstem and frontal locomotor regions degrade, causing start hesitation and freezing. ScienceDirect

17. Genetic MAPT mutations (rare). Rare familial cases with tau mutations can present like PSP. PMC

18. Protein quality-control stress (ER stress, unfolded-protein response). Some PSP risk genes converge on these pathways. PMC

19. Impaired clearance of tau. Reduced proteostasis and glymphatic clearance may contribute to accumulation (mechanistic review context). PMC

20. Environmental contributors (uncertain). Studies explore toxins or exposures, but strong, consistent external causes are unproven. Genetics and biology dominate risk. PMC

Common symptoms

1. Early balance problems and falls. People fall backward or straight down with little warning due to poor postural reflexes. NCBI

2. Slow vertical eye movements. Looking up and down becomes slow, then limited. Reading, stairs, and eating become hard. PMC

3. Double vision or blurry vision when moving the eyes. Because vertical saccades are slow and inaccurate. PMC

4. Axial stiffness and rigid posture. The trunk and neck feel stiff; turning in bed is hard. NCBI

5. Small, shuffling steps or gait freezing. The feet “stick to the floor,” especially in doorways or tight spaces. ScienceDirect

6. Soft, slurred, or effortful speech. Speech can become quiet, monotone, or halting; language planning can also be impaired. PMC

7. Swallowing problems. Coughing with liquids, prolonged meals, weight loss, and aspiration risk. NCBI

8. Slow thinking and planning (executive dysfunction). Tasks that need organization or multitasking become difficult. PMC

9. Apathy or loss of drive. People may seem less motivated or emotionally flat. PMC

10. Impulsivity or poor judgment. Quick decisions without thinking through safety can raise fall risk. PMC

11. Blurred or “jumping” vision while reading. Due to saccadic intrusions (like square-wave jerks) and poor fixation. PMC

12. Eyelid opening problems. The lids may clamp shut (blepharospasm) or have difficulty opening on command. NCBI

13. Depressed mood or anxiety. Mood symptoms can accompany cognitive and motor changes. NCBI

14. Urinary urgency or constipation. Autonomic symptoms can occur but are usually milder than in multiple system atrophy. NCBI

15. Poor response to levodopa. Some variants have a brief or modest response, but most patients get limited benefit over time. NCBI

Diagnostic tests

A) Physical examination (bedside)

1. Vertical saccade test. The clinician asks you to look up and down quickly; slow vertical saccades or gaze palsy strongly suggest PSP. Video-oculography can quantify this. Movement Disorders+1

2. Square-wave jerk observation. While you fixate on a dot, the eyes make frequent tiny jump-back intrusions; common in PSP and now part of updated criteria work. PMC

3. Pull test for postural reflexes. A gentle backward tug checks balance recovery; impaired responses predict early falls. NCBI

4. Gait and freezing assessment. Walking through doorways and turning tests for start hesitation and freezing spells. ScienceDirect

5. Speech and swallowing screen. Listen for hypophonia, slurred or effortful speech; water-swallow test screens aspiration risk. NCBI

6. Frontal/executive bedside tasks. Luria three-step hand sequences, go/no-go, and proverb interpretation probe planning and inhibition. PMC

B) “Manual”/clinic-based functional tests (non-lab, non-imaging tools)

7. Timed Up-and-Go (TUG) and gait freezing questionnaires. Simple performance and patient-reported tools to track mobility and freezing. ScienceDirect

8. Standardized eye-movement bedside battery. Horizontal vs vertical saccade speed and accuracy, antisaccades, and pursuit smoothness. PMC

9. Cognitive screening (MoCA or similar). Brief tests capture executive and attention deficits typical in PSP. PMC

10. Speech–language evaluation. Formal assessment distinguishes apraxia of speech vs aphasia in PSP-SL. PMC

C) Laboratory and pathological tests

11. CSF neurofilament light chain (NfL). Often elevated in PSP and tracks disease severity/progression; useful as a supportive biomarker. PMC+1

12. CSF phosphorylated tau (p-tau181). Patterns differ from Alzheimer’s; lower p-tau can correlate with worse PSP severity. Supportive, not diagnostic alone. PMC

13. Plasma biomarker panels (research/early clinical use). Studies test NfL and other plasma markers to separate PSP from PD/MSA. ScienceDirect

14. Genetic testing (selected cases). MAPT mutation testing in familial or atypical presentations; most PSP is sporadic. PMC

15. Definitive neuropathology (post-mortem). 4R tau-positive threads, tangles, tufted astrocytes confirm diagnosis. (Gold standard in research.) NCBI

D) Electrodiagnostic and physiologic tests

16. Video-oculography (VOG). Quantifies slow vertical saccades and saccadic intrusions with high specificity for PSP vs PD. PubMed+1

17. Polysomnography with electro-oculography (EOG). New work shows characteristic REM eye-movement profiles that may help distinguish PSP. PMC

18. Surface EMG for swallowing/speech (selected centers). Assesses timing and safety of swallow and speech muscle activation to guide therapy. (Supportive physiologic testing.) NCBI

E) Imaging tests

19. Brain MRI (structural). Midbrain atrophy with a preserved pons (the “hummingbird” sign) strongly supports PSP; MR Parkinsonism Index (MRPI) combines midbrain/pons and cerebellar peduncle measures to improve accuracy. PMC+1

20. Advanced imaging (research/selected clinical).
    • DTI/volumetry show brainstem and frontal atrophy patterns;
    • Tau PET seeks tau deposits (limited sensitivity for 4R tau in routine practice);
    • DaT SPECT/PET shows presynaptic dopaminergic loss but is not disease-specific. These can support diagnosis or rule out mimics.

Non-pharmacological treatments (therapies and others)

Each item includes a short description, its purpose, and the main mechanism in simple terms.

1. Specialized physiotherapy (balance & gait training).
   A therapist teaches safe standing, turning, and sit-to-stand strategies, often using cues, metronomes, and progressive balance tasks. Purpose: reduce falls and keep walking as long as possible. Mechanism: repetitive task-specific practice strengthens compensating movement patterns and improves postural control. PubMed+2PMC+2

2. Falls-prevention program (home safety + assistive devices).
   Hazard checks, grab bars, non-slip footwear, weighted walkers/rollators, and caregiver training. Purpose: prevent injuries. Mechanism: environmental changes and steady support reduce center-of-mass sway and trip risk. BMJ Paediatrics

3. Oculomotor/visual strategies (compensatory).
   Teach “head thrust” maneuvers, larger head turns, bright tape targets on steps, and reading with page/line rulers. Purpose: work around vertical gaze palsy in daily tasks. Mechanism: uses neck movement and visual cues to substitute for slow saccades. Frontiers

4. Occupational therapy (ADL adaptation).
   Task simplification, seating, transfer training, bathroom adaptations, and energy-saving routines. Purpose: keep independence. Mechanism: reduces physical demand and leverages assistive tools. pspassociation.org.uk

5. Speech-language therapy (dysphagia).
   Early swallow assessment, texture modification, chin-tuck/postural strategies, and safe swallow pacing. Purpose: reduce choking and weight loss. Mechanism: aligns bolus flow with slower oral phase and impaired laryngeal timing. BMJ Paediatrics+2PMC+2

6. Speech therapy (dysarthria/voice).
   Loudness and breath support drills; communication aids (amplifiers, apps). Purpose: clearer speech. Mechanism: increases respiratory drive and articulatory effort to overcome hypokinetic speech. Frontiers

7. Peg-in-the-ground turning & cueing for freezing.
   Use floor markers and rhythmic cues to initiate steps. Purpose: ease start hesitation. Mechanism: external cues bypass impaired internal motor timing. Frontiers

8. Exercise: strength + flexibility + aerobic activity.
   Gentle resistance, stretching, and regular aerobic (bike or supported treadmill). Purpose: maintain mobility and stamina. Mechanism: improves muscle power, range, and cardiovascular conditioning. PubMed

9. Manual therapy for neck/axial rigidity (adjunct).
   Gentle range-of-motion, heat, and positioning. Purpose: reduce stiffness and pain. Mechanism: soft-tissue mobilization improves comfort and posture. Frontiers

10. Low-vision adaptations.
    Large-print labels, high-contrast edges, extra lighting, and audio readers. Purpose: safer navigation and reading with limited vertical gaze. Mechanism: compensates reduced saccade amplitude. Frontiers

11. Nutritional support and weight monitoring.
    High-calorie, easy-to-chew foods; frequent small meals; thickeners when needed. Purpose: prevent malnutrition and dehydration. Mechanism: matches food texture to swallow function and increases caloric density. BMJ Paediatrics

12. Advance care planning and caregiver education.
    Discuss goals, risks, feeding options, and support services early. Purpose: informed choices; reduced crisis decisions. Mechanism: anticipatory guidance in a progressive condition. BMJ Paediatrics

13. Sleep hygiene program.
    Regular sleep/wake times, light exposure, limit naps, evaluate for sleep apnea. Purpose: reduce daytime sleepiness and fragmentation. Mechanism: strengthens circadian rhythm and sleep quality. Frontiers+1

14. Cognitive-behavioral strategies for apathy and mood.
    Structured day plans, rewarding activities, caregiver cueing. Purpose: improve engagement. Mechanism: external structure compensates for frontal executive deficits. PMC+1

15. Emotional expression coaching (pseudobulbar affect).
    Education and trigger management; safety plans for sudden crying/laughing. Purpose: reduce distress. Mechanism: reframing and behavior strategies around brain-driven episodes. PMC

16. Sialorrhea self-management.
    Timed swallows, posture, hard candy/lozenges to stimulate swallow, dental suction devices. Purpose: reduce drooling and skin irritation. Mechanism: increases swallow frequency and saliva clearance. PMC

17. Community exercise groups (when feasible).
    Supervised classes for balance and stretching. Purpose: maintain activity and social contact. Mechanism: motivation and safe repetition. PSP

18. Driving and mobility counseling.
    Early screening; switch to escorted transport. Purpose: safety. Mechanism: recognizes early oculomotor/postural risks. BMJ Paediatrics

19. Respiratory and aspiration risk checks.
    Early evaluation after cough/choking events; vaccines per local guidance. Purpose: prevent pneumonia. Mechanism: reduces aspiration burden and infection risk. BMJ Paediatrics

20. Feeding-tube education (PEG) when appropriate.
    Discuss options before severe weight loss. Purpose: maintain nutrition/hydration safely. Mechanism: bypasses unsafe swallow while honoring goals of care. nhs.uk+1

---

Drug treatments

Important: These are common clinical choices for symptoms in PSP; responses vary, and many have limited or mixed evidence in PSP compared with Parkinson’s disease. Always individualize with a neurologist.

1. Levodopa/carbidopa.
   Class: dopaminergic replacement. Dose/Time: often titrated to 300–900 mg/day levodopa in divided doses (e.g., 100/25 mg TID), adjusted to response/tolerance. Purpose: trial for rigidity/bradykinesia; a minority benefit. Mechanism: replenishes dopamine. Side effects: nausea, low blood pressure, hallucinations, dyskinesia (less common in PSP). Evidence suggests only a subset (~15–30%) show meaningful benefit. PMC+2PMC+2

2. Amantadine.
   Class: antiglutamatergic/dopaminergic modulator. Dose: 100 mg once–three times daily. Purpose: trial for gait freezing, rigidity, fatigue. Mechanism: NMDA antagonism; increases dopamine release. Side effects: swelling, livedo reticularis, confusion. Recent analyses show subjective benefit in some, but no clear objective PSPRS improvement overall. PMC+2American Academy of Neurology+2

3. Zolpidem (select cases).
   Class: GABA-A (α1) agonist hypnotic. Dose: small test doses (e.g., 5–10 mg, supervised). Purpose: rare short-term improvements in eye movements or motor function reported. Mechanism: modulates inhibitory circuits. Side effects: sedation, falls; not routine. Evidence is from small studies/case reports. New England Journal of Medicine+2ScienceDirect+2

4. Botulinum toxin (for dystonia/blepharospasm).
   Class: neuromuscular blocker (local injection). Dose: individualized per muscles (e.g., orbicularis oculi) every ~3 months. Purpose: reduce eyelid spasm, neck/limb dystonia. Mechanism: blocks acetylcholine at neuromuscular junction. Side effects: local weakness, dry eye. Evidence supports benefit for blepharospasm/dystonia in PSP and PD. PMC+2ScienceDirect+2

5. Anticholinergics for drooling (glycopyrrolate, topical atropine).
   Class: antimuscarinic. Dose: glycopyrrolate 1 mg TID (titrate); atropine 1% drops sublingual (off-label, very small doses). Purpose: reduce sialorrhea. Mechanism: lowers saliva production. Side effects: dry mouth, constipation, confusion (use caution). RCTs in PD show benefit; often extrapolated to PSP. PubMed+2PMC+2

6. Botulinum toxin to salivary glands (BoNT-A or BoNT-B).
   Class: local chemodenervation. Dose: ultrasound-guided parotid/submandibular injections; intervals ~3 months. Purpose: drooling when oral meds are not tolerated. Mechanism: reduces salivary output. Side effects: dry mouth, thick saliva. RCTs support use in PD; commonly applied in PSP. JAMA Network+2American Academy of Neurology+2

7. Selective serotonin reuptake inhibitors (e.g., sertraline, citalopram).
   Class: SSRI antidepressant. Dose: standard SSRI dosing; start low. Purpose: treat depression/anxiety; sometimes helps emotional lability. Mechanism: increases serotonin signaling. Side effects: GI upset, hyponatremia, bleeding risk. Depression can co-occur; apathy may mimic depression, so evaluation is key. PMC+1

8. Dextromethorphan/quinidine (for pseudobulbar affect).
   Class: NMDA/σ-1 modulator + CYP inhibitor (enables DM exposure). Dose: 20/10 mg once daily x7 days, then 20/10 mg BID (standard labeling). Purpose: reduce sudden crying/laughing episodes. Mechanism: modulates excitatory neurotransmission affecting emotional expression. Side effects: dizziness, QT prolongation, interactions. Strong evidence in ALS/MS; used off-label in other brain disorders. JAMA Network+2PubMed+2

9. Atypical antipsychotics (very cautious, e.g., quetiapine).
   Class: serotonin/dopamine antagonist. Dose: very low at night, titrate. Purpose: distressing hallucinations/behavior when other causes excluded. Mechanism: reduces dopaminergic psychosis. Side effects: sedation, orthostasis; avoid potent D2 blockers which can worsen parkinsonism. Expert practice pieces emphasize careful, minimal use. BMJ Paediatrics

10. Melatonin (sleep).
    Class: chronobiotic. Dose: 2–5 mg at night. Purpose: insomnia/fragmented sleep. Mechanism: strengthens circadian rhythm. Side effects: morning grogginess. Sleep disturbance is common in PSP. Frontiers

11. Modafinil (daytime sleepiness/apathy in select cases).
    Class: wake-promoting agent. Dose: 100–200 mg morning (specialist guidance). Purpose: reduce EDS, possibly apathy. Mechanism: enhances wake circuits. Side effects: headache, insomnia, BP elevation; evidence in PSP is limited to small reports/consensus notes. ScienceDirect+1

12. Baclofen or tizanidine (spasticity/dystonia adjunct).
    Class: GABA-B agonist / α2-agonist. Dose: start very low; titrate. Purpose: reduce painful stiffness. Mechanism: reduces spinal reflex hyperexcitability. Side effects: sedation, weakness, dry mouth. Expert reviews discuss symptomatic use. Frontiers

13. Prucalopride / laxatives (constipation).
    Class: prokinetic/5-HT4 agonist or osmotics. Dose: per label. Purpose: relieve constipation, improve comfort. Mechanism: increases gut motility or water content. Side effects: diarrhea, cramps. (General symptomatic care guidance.) BMJ Paediatrics

14. Proton-pump inhibitor if reflux worsens dysphagia/cough.
    Class: acid suppression. Dose: per label. Purpose: reduce reflux/aspiration risk. Mechanism: lowers gastric acidity. Side effects: hypomagnesemia, C. difficile risk (long term). (Supportive management.) BMJ Paediatrics

15. Anticholinergic eye drops/tears (for exposure/dry eye from reduced blink).
    Class: lubricants (not anticholinergic for this use). Dose: artificial tears ≥4×/day. Purpose: protect cornea with blepharospasm/apraxia. Mechanism: increases tear film. Side effects: blur briefly. (Symptom care referenced in practice reviews.) BMJ Paediatrics

16. Pain management (acetaminophen; cautious NSAIDs).
    Class: analgesics. Dose: per label; avoid NSAIDs in high GI/renal risk. Purpose: musculoskeletal pain from rigidity/falls. Mechanism: central/peripheral analgesia. Side effects: GI, renal, CV risks with NSAIDs. (General symptomatic principles.) BMJ Paediatrics

17. Sialorrhea: ipratropium nasal spray used sublingually (off-label).
    Class: antimuscarinic. Dose: very small sublingual sprays (specialist guided). Purpose: drooling without systemic effects. Mechanism: local saliva reduction. Side effects: mouth dryness, minimal CNS penetration. PMC

18. Orthostatic hypotension management (midodrine or fludrocortisone when present).
    Class: α1-agonist / mineralocorticoid. Dose: per label; monitor BP/electrolytes. Purpose: reduce dizziness/falls in susceptible patients. Mechanism: raises vascular tone or volume. Side effects: hypertension, edema, hypokalemia. (General autonomic care extrapolated.) BMJ Paediatrics

19. Antiemetics with low EPS risk if needed (ondansetron).
    Class: 5-HT3 antagonist. Dose: per label. Purpose: treat nausea (e.g., from meds). Mechanism: serotonin blockade in gut/CTZ. Side effects: constipation, QT. (Symptomatic principle.) BMJ Paediatrics

20. Avoid/stop meds that worsen cognition/balance (e.g., strong anticholinergics, sedatives) when possible.
    Purpose: protect thinking and reduce falls. Mechanism: minimize drug-induced impairment. Note: review med lists regularly with clinicians. BMJ Paediatrics

Why not “disease-modifying” drugs? Large trials targeting tau (e.g., tilavonemab) and microtubule-stabilizing peptides (davunetide) have not shown slowing of PSP. Coenzyme Q10 showed small short-term metabolic signals but no clear long-term clinical benefit. Research continues. PMC+4The Lancet+4The Lancet+4

---

Dietary molecular supplements

There is no supplement proven to stop PSP. Use these only as adjuncts after discussing with clinicians, especially due to drug interactions.

1. Coenzyme Q10.
   Dose studied: 100–300 mg/day (varied). Function: mitochondrial support. Mechanism: electron transport chain cofactor. Evidence: RCTs in PSP did not show meaningful clinical slowing; small metabolic improvements reported. PMC+2PubMed+2

2. Creatine.
   Dose: 3–5 g/day. Function: cellular energy buffer. Mechanism: phosphocreatine system. Evidence: mixed/negative in parkinsonian disorders; none showing disease modification in PSP. (General synthesis.) Frontiers

3. Omega-3 fatty acids.
   Dose: ~1 g/day EPA+DHA. Function: anti-inflammatory, cardiovascular. Mechanism: membrane lipid effects, resolvins. Evidence: no PSP-specific trials; consider for heart health. BMJ Paediatrics

4. Vitamin D (if deficient).
   Dose: per lab results. Function: bone/muscle health, falls risk reduction in deficiency. Mechanism: calcium/neuromuscular effects. Evidence: general geriatric benefit if deficient; not PSP-specific disease modification. BMJ Paediatrics

5. Thickeners (technically a food product).
   Dose: per swallow plan. Function: make liquids safer. Mechanism: slows flow to match swallow timing. Evidence: standard dysphagia practice. BMJ Paediatrics

6. High-calorie oral nutritional supplements.
   Dose: 1–2 servings/day as needed. Function: weight maintenance. Mechanism: calorie/protein density. Evidence: nutrition best-practice in neurodegenerative dysphagia. BMJ Paediatrics

7. Caffeine (timed, modest).
   Dose: equivalent 1–2 cups coffee AM. Function: alertness. Mechanism: adenosine receptor antagonism. Evidence: symptomatic only; watch tremor/insomnia. Frontiers

8. Fiber (psyllium/inulin) + hydration.
   Dose: ~5–10 g/day fiber supplement. Function: constipation help. Mechanism: stool bulk/softness. Evidence: general GI benefit. BMJ Paediatrics

9. Probiotics (if constipation/bowel issues).
   Dose: per product. Function: gut motility and stool consistency. Mechanism: microbiome. Evidence: general; PSP-specific data lacking. BMJ Paediatrics

10. Avoid unproven “neuro-booster” blends.
    Why: no evidence for disease modification; cost/interaction risks. Mechanism: —. Advice: discuss supplements with clinicians. PubMed

---

Immunity-booster / regenerative / stem-cell drugs

Key point: There are no proven immune or stem-cell drugs that slow PSP. Below are items patients often ask about—with what we know.

1. Tilavonemab (anti-tau mAb).
   Use: research only; not effective in phase 2. Mechanism: targets extracellular tau to block spread. Dose: trial protocols only. The Lancet+1

2. Davunetide (NAP).
   Use: research; negative phase 2/3. Mechanism: microtubule-stabilizing peptide. Dose: trial only. PMC+1

3. Coenzyme Q10 (as “neuroprotective”).
   Use: supplement; trials did not show clinical slowing. Mechanism: mitochondrial support. Dose: varied in studies. PMC

4. Other anti-tau antibodies (class).
   Use: research; multiple Alzheimer’s and PSP programs negative to date. Mechanism: binds tau species. Dose: trial only. PMC+1

5. Stem cell infusions.
   Use: not recommended outside trials; no proven benefit in PSP, potential risks. Mechanism: theoretical neurorepair. Dose: —. (Consensus reviews urge caution.) PubMed

6. “Immune boosters” (over-the-counter).
   Use: no evidence to modify PSP. Mechanism: marketing claims vary. Advice: avoid high-dose, interacting products. PubMed

---

Procedures / surgeries

1. PEG feeding tube.
   What: small tube into stomach for nutrition/fluids/meds. Why: severe dysphagia, weight loss, dehydration, long mealtimes, aspiration risk. Discuss early with team to align with goals. nhs.uk+1

2. Botulinum toxin injections (eyelids/neck/limbs).
   What: in-clinic injections into overactive muscles. Why: blepharospasm or focal dystonia causing pain or functional block. PMC

3. Botulinum toxin to salivary glands.
   What: parotid/submandibular gland injections. Why: troublesome drooling not controlled by tablets, to reduce aspiration/skin issues. JAMA Network

4. Eye care procedures (lubrication regimes; rarely surgical eyelid interventions).
   What: aggressive lubrication; selective procedures for eyelid opening apraxia in select centers. Why: protect cornea and vision comfort. BMJ Paediatrics

5. Feeding-related endoscopic care and aspiration management.
   What: endoscopic assessments; manage reflux/strictures. Why: reduce aspiration pneumonia risk and maintain comfort. BMJ Paediatrics

(Deep brain stimulation is not effective for core PSP features and is not recommended.) BMJ Paediatrics

---

Prevention tips

1. Early home safety review (remove rugs, add grab bars, good lighting). Why: cut fall risk. BMJ Paediatrics

2. Use the right walker/rollator (often a weighted or U-frame type). Why: stability for forward falls. Frontiers

3. Daily balance/strength practice with therapist plan. Why: maintain reserve. PubMed

4. Swallow screening early and often. Why: prevent choking/weight loss. BMJ Paediatrics

5. Vaccinations per local guidance (flu, pneumococcal). Why: lower pneumonia risk. BMJ Paediatrics

6. Medication reviews to remove sedating/anticholinergic agents. Why: reduce falls/confusion. BMJ Paediatrics

7. Pressure-relief routine (seating, cushions). Why: skin protection as mobility drops. BMJ Paediatrics

8. Sleep hygiene (consistent schedule, daylight). Why: reduce daytime sleepiness. Frontiers

9. Nutrition plan (high-calorie, easy textures, supplements as needed). Why: sustain weight/energy. BMJ Paediatrics

10. Eye care routine (artificial tears, sunglasses, brimmed hat). Why: comfort and safety outdoors. BMJ Paediatrics

---

When to see a doctor (red flags)

• Choking, pneumonia, or weight loss despite diet changes (urgent): need swallow reassessment and nutrition plan; consider PEG discussion. BMJ Paediatrics

• New or frequent falls, fainting, or severe dizziness: mobility device review; check blood pressure and meds. BMJ Paediatrics

• Severe drooling causing skin breakdown or aspiration risk: consider botulinum injections or medication changes. JAMA Network

• Distressing emotional outbursts (crying/laughing): evaluate for pseudobulbar affect; DM/Q may help. JAMA Network

• Confusion, hallucinations, or sudden sedation after a new drug: adjust medicines. BMJ Paediatrics

• Severe eye problems (pain, redness, vision changes) or inability to open eyes: urgent eye care and spasm treatment. PMC

---

What to eat and what to avoid

1. Do: soft, moist, high-calorie foods (eggs, yogurt, mashed legumes, smoothies). Why: easier, safer swallowing and weight maintenance. BMJ Paediatrics

2. Do: small, frequent meals with rest breaks. Why: reduces fatigue. BMJ Paediatrics

3. Do: thickened liquids if recommended. Why: lowers aspiration risk. BMJ Paediatrics

4. Do: adequate fluids (per swallow plan). Why: prevent dehydration/constipation. BMJ Paediatrics

5. Do: fiber-rich sides (oats, prunes) or supplements. Why: constipation relief. BMJ Paediatrics

6. Avoid: dry, crumbly, mixed-texture foods (nuts, crackers, thin soups with chunks) unless cleared. Why: choking risk. BMJ Paediatrics

7. Avoid: alcohol or heavy evening caffeine if sleep is poor. Why: worsens insomnia/falls. Frontiers

8. Do: consider oral nutrition shakes if weight is dropping. Why: easy calories/protein. BMJ Paediatrics

9. Do: sit upright 30 minutes after meals. Why: reduce reflux/aspiration. BMJ Paediatrics

10. Avoid: starting new supplements without checking interactions. Why: no proven disease-modifying effect; possible risks. PubMed

---

Frequently asked questions

1. Is PSP the same as Parkinson’s disease?
   No. PSP is a different disease with 4R-tau buildup and early eye movement problems and falls; responses to Parkinson’s drugs are usually limited. PMC+1

2. What does “atypical PSP” mean?
   It means the symptoms don’t fit the classic pattern exactly—for example, more speech/language or parkinsonism features—but the underlying disease is still PSP. PubMed

3. How is PSP diagnosed?
   Doctors use Movement Disorder Society (2017) clinical criteria that weigh eye signs, falls, and other features; MRI and other tests help rule out mimics. PubMed

4. Is there a cure?
   No cure yet. Studies targeting tau (tilavonemab) and other strategies (davunetide) have not slowed the disease. Care focuses on symptoms and safety. The Lancet+1

5. Do people with PSP ever respond to levodopa?
   Some do—a minority show helpful improvement in stiffness or slowness. Many notice little change. A supervised trial is reasonable. PMC+1

6. Can therapy really help if medicines don’t?
   Yes. Physiotherapy, occupational therapy, and speech-language therapy improve day-to-day safety, function, and quality of life even without curing the disease. PubMed+1

7. What about amantadine?
   Some patients report feeling better, but recent studies did not show clear objective improvements on PSP scales overall. Side effects can limit use. American Academy of Neurology

8. Why are eye movements so hard?
   PSP damages brainstem and frontal circuits that make fast vertical eye jumps (saccades), so people use head turns and visual tricks to compensate. PubMed

9. Is botulinum toxin safe for eyelid spasm or drooling?
   When given by trained clinicians, it can help both problems with acceptable safety; dosing is individualized. PMC+1

10. What can we do about sudden crying or laughing (PBA)?
    Behavioral strategies help. Dextromethorphan/quinidine can reduce episodes; discuss risks/benefits with your doctor. JAMA Network

11. Will a feeding tube be needed?
    Sometimes. If eating becomes unsafe or too slow and weight is falling, a PEG tube may improve comfort and nutrition. Decide based on personal goals. nhs.uk

12. Are stem cells or “immune boosters” recommended?
    Not currently. There’s no proven benefit for PSP and there may be risks. Consider only in well-run clinical trials. PubMed

13. Can sleep improve?
    Yes—sleep hygiene, treating apnea, and sometimes melatonin or other clinician-guided options can help. Frontiers

14. What is the outlook?
    PSP is progressive at different speeds for different people. Early planning, therapy, and symptom care make a major difference in quality of life. BMJ Paediatrics

15. Where can we learn more and get support?
    PSP organizations publish practical guides for therapists, patients, and carers, and can help find specialized centers

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 28, 2025.